Celldex (CLDX) to Discontinue RINTEGA Phase 3 ACT IV Study Following IDSMB Determination

March 7, 2016 7:01 AM EST Send to a Friend
Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login